Vaccines, Blood & Biologics
RiaSTAP
Proper Name: Fibrinogen Concentrate (Human)
Tradename: RiaSTAP
Manufacturer: CSL Behring GmbH, License # 1765
- Package insert (PDF, 220 KB) - January 2009
Date: January 16, 2009
Indication: For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia).
January 16, 2009 Approval Letter
Press Release: FDA Approves RiaSTAP for Treatment of Bleeding in Patients with Rare Genetic Defect - January 16, 2009
Summary Basis for Regulatory Action (PDF - 689 KB)
Approval History, Letters, Reviews, and Related Documents
Contact FDA
Division of Communication and Consumer Affairs
Office of Communication, Outreach and Development
Food and Drug Administration
1401 Rockville Pike
Suite 200N/HFM-47
Rockville, MD 20852-1448